Cancer research is big business, and with big business comes big corruption. The embattled International Agency for Research on Cancer (IARC), based in Lyon, France, is in Congress’s crosshairs again. The U.S. House Science, Space and Technology (SST) Committee has been concerned about IARC’s scientific integrity—and the millions of dollars of funding it receives from American taxpayers—since 2016. Dr. Elisabete Weiderpass, a Brazilian scientist who was recently chosen to take over the reins of IARC in January 2019. The SST has officially asked Weiderpass to testify at a July hearing to explain how she will manage the agency better than her predecessor, whose tenure the Congressional committee called “an affront to scientific integrity.”..........
Congress has made it clear that despite this history of supporting the status quo, it is looking for Weiderpass to usher in genuine change, which needs to begin with her testifying before the committee. If she continues IARC’s tradition of snubbing American lawmakers, then it’s high time to make good on threats to pull the agency’s U.S. government funding. America can no longer afford to foot the bill for IARC’s cushy new offices in France and third-rate science.
.............To Read More.....
Congress has made it clear that despite this history of supporting the status quo, it is looking for Weiderpass to usher in genuine change, which needs to begin with her testifying before the committee. If she continues IARC’s tradition of snubbing American lawmakers, then it’s high time to make good on threats to pull the agency’s U.S. government funding. America can no longer afford to foot the bill for IARC’s cushy new offices in France and third-rate science.
.............To Read More.....
No comments:
Post a Comment